Stabilized immunoglobulins
US7608260B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 5, 2004 |
| Grant date | Oct 27, 2009 |
| Priority date | — |
| Expiry date | Apr 19, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/53
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention provides stabilized immunoglobulin molecules that have increased storage stability and/or in vivo half-lives due to the mutation of one or more amino acids that would otherwise render the immunoglobulin molecules susceptible to degradation. In a preferred embodiment, the stabilized immunoglobulins of the invention have mutations at the heavy chain constant domain hinge region. Such stabilized immunoglobulin molecules, i.e., immunoglobulin molecules with increased storage stability have one or more of the following advantages they are more readily transported and/storable for longer periods and/or less stringent conditions than non-stabilized counterparts; that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such stabilized molecules.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.